Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 5/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17115482 | 1.00 | HPGD (0.33) | HPGDMAPK1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL18707022 | 0.98 | HPGD (0.33) | HPGDMAPK1SMN1; SMN2RORCMEN1 | |
| SCHEMBL17115381 | 0.95 | PTGER4 (0.33) | HPGDMAPK1SMN1; SMN2RORCPTGER4 | |
| SCHEMBL17115369 | 0.92 | PTGER4 (0.32) | PTGER4 | |
| SCHEMBL17115372 | 0.89 | PTGER4 (0.32) | HPGDMAPK1SMN1; SMN2PTGER4 | |
| SCHEMBL17115461 | 0.88 | — | — | |
| SCHEMBL20115845 | 0.88 | CYP1A2 (0.35) | MAPK1CYP1A2CYP2D6CYP2C19RORC | |
| SCHEMBL20115892 | 0.88 | CYP1A2 (0.35) | MAPK1CYP1A2CYP2D6CYP2C19RORC | |
| SCHEMBL17115464 | 0.86 | RORC (0.32) | RORCPTGER4 | |
| SCHEMBL20116773 | 0.86 | PGR (0.35) | MAPK1CYP1A2CYP2D6CYP2C19RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170098781-A1 | NEW DIBENZOFURANS AND DIBENZOTHIOPHENES | IDEMITSU KOSAN CO., LTD. (JP) | 2017-04-06 | — | — | US | disclosed |
| WO-2015140073-A1 | NEW DIBENZOFURANS AND DIBENZOTHIOPHENES | IDEMITSU KOSAN CO., LTD. (JP) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170098781-A1 | NEW DIBENZOFURANS AND DIBENZOTHIOPHENES | DBF4, DDT, SLC43A3 | HPGD 1982/4885MAPK1 1132/4885SMN1; SMN2 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.